Projects per year
RESOLUTE: A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils
Dabscheck, E. & Hazard, A.
30/06/20 → 31/12/23
Hamilton, J. & Chen, V.
1/01/20 → 31/12/23
A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012).
Roberts, S. & Lewis, P.
5/06/20 → 31/12/23
1/01/19 → 31/12/23
Understanding how group 2 innate lymphoid cells in early-life regulate postnatal lung development and susceptibility
1/07/20 → 31/12/23
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study.
Haydon, A. & Cross, N.
21/11/18 → 31/12/23
A randomized, double-blind, placebo-controlled, parallel group, multicenter trial of CVL-865 as adjunctive therapy in adults with drug-resistant focal onset seizures (REALIZE TRIAL)
O'Brien, T., Perucca, P., Nikpour, A., Wijayath, M., D'Souza, W. J., Reutens, D. C., Carney, P., Somerville, E. R. & Berkovic, S. F.
5/06/20 → 31/12/23
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
Sparrow, M. & McKenzie, J.
21/05/20 → 31/12/23
An Open-Label Study To Evaluate The Long-Term Safety Of Daily Oral BCX7353 In Subjects With Type I and II Hereditary Angioedema.
Zubrinich, C., Malinowski, L. & Thompson, K.
27/07/18 → 31/12/23
A Therapeutic Intervention, Open Label Study to Compare the Efficacy and Safety of Graded Exercise Compared to Passive Stretching in Subjects Who Have Sustained a Mild Traumatic Brain Injury
O'Brien, T., Barlow, K., Levi, C. & Jankelowitz, S.
5/05/20 → 31/12/23
A randomised controlled trial of Focal Electrically Administered Seizure Therapy (FEAST) in patients with severe depression
Loo, C., Martin, D., Fitzgerald, P., Dokos, S., Hadzi-Pavlovic, D., George, M., Bai, S. & Boonstra, T.
1/01/19 → 31/12/23
Early HomeBase pulmonary rehabilitation after hospital in chronic obstructive pulmonary disease (COPD)
7/10/19 → 31/12/23
A Phase 1, Open-label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy in Patients with Advanced Solid Tumors and Hematological Malignancies.
Voskoboynik, M., Tran, B., Gan, H. K. & Hawkins, C.
23/07/20 → 31/12/23
Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started on fingolimod once daily or treated with another disease-modifying therapy.
Van Der Walt, A. & Germaine, J.
30/11/18 → 31/01/24
Patil, S. & Kennedy, N.
20/02/19 → 29/02/24
A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (D-VRd) in Subjects with Previously Untreated Multiple Myeloma who are Eligible for High-Dose Therapy.
Spencer, A. & Kennedy, N.
13/02/19 → 29/02/24
1/04/20 → 31/03/24
Evaluating the effectiveness and safety of sodium selenate as a disease modifying treatment for patients with behavioural variant Frontotemporal Dementia (bvFTD)
O'Brien, T., Malpas, C., Velakoulis, D., Brodtmann, A., Piguet, O., Kalincik, T., Walterfang, M., Ahmed, R., Bush, A. I. & Darby, D. G.
1/04/19 → 31/03/24
1/04/20 → 31/03/24
Clinical Study No. M15-563, An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP).
Bertram, K. & Burn, K.
3/04/19 → 30/04/24
A phase 1b, multi-arm, open-label, study of HDM201 in combination with MBG453 or venetoclax in adult subjects with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
Wei, A. & Kennedy, N.
23/05/19 → 23/05/24
Autoimmune Encephalitis - a rare and debilitating neurological illness affecting the Australian population. A study of the Australian Autoimmune Encephalitis Consortium.
1/06/20 → 31/05/24
A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients.
4/07/19 → 31/05/24
Ong, J., Tucker, J. D. & Iwelunmor, J.
1/09/18 → 31/08/24
A Phase 3, multicentre, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL 112 in subjects with Acute Coronary Syndrome protocol #: CSL 112_3001 (the ApoA-1 Event ReducinG in Ischaemic Syndromes II (AEGIS-II) Study.
1/10/18 → 1/10/24
EPO-TRAUMA: ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients: a multicentre, stratified, double blind, placebo randomised controlled trial. (The EPO-TRAUMA trial)
French, C., Nichol, A., Bellomo, R., Cooper, J., Bailey, M., Higgins, L., McArthur, C., Hodgson, C., Gabbe, B., Duranteau, J., Presneill, J., Rosenfeld, J., Napolitano, L., Skrifvars, M., Reade, M. & Pettila, V.
1/04/19 → 1/10/24
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Locally Advanced Rectal Cancer: A Multicentre Randomised Study. (DYNAMIC-RECTAL).
Gill, S. & Cross, N.
30/09/18 → 30/10/24
A translational framework for discovering novel solutions for drug resistance in acute myeloid leukaemia
1/01/20 → 31/12/24
A phase 3, open-label, randomised study to compare the efficacy and safety of luspatercept (Ace-536) versus epoetin alfa for the treatment of anaemia due to Ipss-R very low, low or intermediate risk myelodysplastic syndromes (MDS) in ESA naive subjects who require red blood cell transfusions [ACE-536-MDS-002]
Kenealy, M. & Baker, E.
20/12/18 → 31/12/24
A phase 1/1b study to evaluate the safety and tolerability of immunotherapy combinations in participants with gastrointestinal malignancies [AB928CSP0003].
Richardson, G. & Baker, E.
28/02/19 → 31/12/24
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630).
Chipman, M., Hawkins, C. & Cross, N.
12/08/19 → 31/12/24
A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching from Treatment with 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment.
16/04/19 → 31/12/24